Novo Nordisk's Raised Forecast Fails to Convince Wall Street Amid Eli Lilly Competition
Guidance·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Novo Nordisk has raised its earnings forecast, but Wall Street remains skeptical about the company's ability to achieve sustainable growth. The skepticism is fueled by increasing competition from Eli Lilly in the obesity treatment market.
Despite the optimistic guidance, analysts are not convinced that Novo Nordisk has a clear path forward, as the rivalry with Eli Lilly intensifies, particularly in the market for obesity drugs like Ozempic.
Novo NordiskEli Lilly
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.”
CNBC — Novo Nordisk's raised forecast fails to change the debate over its obesity business